The National Institute for Health and Care Excellence has recommended a drug that can delay the onset of type 1 diabetes, the first time the NHS has approved a therapy designed to slow the disease's progression rather than treat its effects after they appear. The final draft guidance, published on 23 June 2026, marks a departure from decades of diabetes care in which clinical intervention has begun only once symptoms are present.

The treatment is intended for adults and children aged eight and over who have been identified as having stage 2 type 1 diabetes, a pre-symptomatic phase in which autoimmune activity is already under way but the characteristic signs of the condition have not yet emerged. Reaching patients at this stage has long been a goal of diabetes research, and the approval gives clinicians a formal route to act before the disease takes hold.

Clinical trial data underpinning the NICE recommendation shows that teplizumab can delay the transition from stage 2 to stage 3 disease by an average of nearly three years. For patients and families, that means postponing the point at which insulin therapy becomes necessary and daily management of blood sugar levels begins. The scale of that delay, sustained across a trial population, was sufficient for NICE to conclude the drug merits NHS funding.

The therapy is sold under the brand name Tzield and is manufactured by Sanofi. It is given as a single course of intravenous infusions administered once daily over 14 consecutive days, after which no further treatment is required. That structure distinguishes it from most chronic disease therapies, where patients remain on medication indefinitely. The one-off nature of the course was a relevant factor in NICE's assessment of its overall value.

The guidance does not ignore the demands the treatment places on patients. Attending hospital every day for a fortnight presents real difficulties, particularly for families with children, those in rural areas, or people in employment with limited flexibility. NICE acknowledged these pressures but concluded that because the course is finite and not repeated, the practical burden does not outweigh the clinical benefit. Whether NHS services can accommodate the infusion capacity required at scale is a question that implementation will need to address.

England is now the first country in Europe to approve routine access to teplizumab through a formal health technology appraisal process. That distinction reflects both the speed of the NICE review and the strength of the evidence submitted. For health leaders working on diabetes policy, the decision represents a shift in how type 1 diabetes can be approached: not as a condition to be managed from diagnosis, but as one in which earlier biological intervention is now possible and funded.

The broader implications extend to how pre-symptomatic diabetes is identified in the first place. Offering teplizumab to those with stage 2 disease presupposes that those individuals have been screened and confirmed to be at that stage, something that does not routinely happen across the general population. The NHS will need to consider how screening pathways interact with treatment eligibility, and whether current arrangements are sufficient to reach the patients who stand to benefit. Without that infrastructure, the impact of the approval will remain limited to those already in contact with specialist services through family history or prior testing.

The publication of final draft guidance does not itself trigger immediate NHS access; further steps in the appraisal and commissioning process typically follow. Nevertheless, the NICE recommendation sets a clear direction. For a condition that has resisted modification for generations, the approval of a drug that meaningfully delays its arrival is a substantive development in how British medicine approaches type 1 diabetes.